Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Filippi

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Clinical and Translational Radiation Oncology|March 11, 2026
Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapyAndrea R Filippi, Jair Bar, Daniel C Christoph, et al.
Journal of Bone Oncology|July 26, 2018
Bone metastases in biliary cancers: A multicenter retrospective surveyD Santini, G Brandi, G Aprile, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R StudyNicolas Girard, Jair Bar, Pilar Garrido, et al.
ESMO Open|June 4, 2024
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-RA R Filippi, J Bar, C Chouaid, et al.
British Journal of Cancer|April 10, 2014
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancerL Fornaro, S Cereda, G Aprile, et al.
ESMO Open|February 5, 2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 8, 2017
Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung diseaseS Tanadini-Lang, J Rieber, A R Filippi, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 2, 2020
COVID-19 Outbreak and Cancer Radiotherapy Disruption in Lombardy, Northern ItalyB A Jereczek-Fossa, M F Palazzi, C P Soatti, et al.
The Lancet. Respiratory Medicine|March 27, 2026
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaborationAnne-Marie C Dingemans, Isabelle Opitz, Alessandro Brunelli, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer GroupMariana Brandão, Elena Prisciandaro, Eleni Xenophontos, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Clinical and Translational Radiation Oncology|March 11, 2026
Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapyAndrea R Filippi, Jair Bar, Daniel C Christoph, et al.
Journal of Bone Oncology|July 26, 2018
Bone metastases in biliary cancers: A multicenter retrospective surveyD Santini, G Brandi, G Aprile, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R StudyNicolas Girard, Jair Bar, Pilar Garrido, et al.
ESMO Open|June 4, 2024
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-RA R Filippi, J Bar, C Chouaid, et al.
British Journal of Cancer|April 10, 2014
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancerL Fornaro, S Cereda, G Aprile, et al.
ESMO Open|February 5, 2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 8, 2017
Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung diseaseS Tanadini-Lang, J Rieber, A R Filippi, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 2, 2020
COVID-19 Outbreak and Cancer Radiotherapy Disruption in Lombardy, Northern ItalyB A Jereczek-Fossa, M F Palazzi, C P Soatti, et al.
The Lancet. Respiratory Medicine|March 27, 2026
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaborationAnne-Marie C Dingemans, Isabelle Opitz, Alessandro Brunelli, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer GroupMariana Brandão, Elena Prisciandaro, Eleni Xenophontos, et al.
Pageof 7